HC Wainwright Brokers Raise Earnings Estimates for SLNO

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Analysts at HC Wainwright lifted their Q1 2026 earnings per share estimates for shares of Soleno Therapeutics in a research report issued on Wednesday, March 4th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of $0.93 for the quarter, up from their previous forecast of $0.88. HC Wainwright has a “Buy” rating and a $100.00 price target on the stock. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share. HC Wainwright also issued estimates for Soleno Therapeutics’ Q2 2026 earnings at $1.02 EPS and FY2027 earnings at $7.50 EPS.

Soleno Therapeutics (NASDAQ:SLNO) last issued its quarterly earnings results on Wednesday, February 25th. The company reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.16. The business had revenue of $91.73 million for the quarter, compared to analyst estimates of $88.55 million.

Several other analysts have also weighed in on SLNO. Zacks Research lowered Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 3rd. Wells Fargo & Company lowered their price objective on shares of Soleno Therapeutics from $114.00 to $110.00 and set an “overweight” rating on the stock in a research note on Friday, February 27th. Wolfe Research set a $60.00 target price on shares of Soleno Therapeutics in a report on Monday, January 12th. Wall Street Zen cut Soleno Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Finally, Robert W. Baird set a $107.00 price objective on Soleno Therapeutics in a research note on Tuesday, January 13th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Soleno Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $106.85.

Soleno Therapeutics Trading Up 1.1%

Shares of NASDAQ:SLNO opened at $38.13 on Thursday. Soleno Therapeutics has a twelve month low of $32.63 and a twelve month high of $90.32. The company has a current ratio of 5.80, a quick ratio of 5.55 and a debt-to-equity ratio of 0.11. The firm has a market cap of $1.97 billion, a P/E ratio of 165.79 and a beta of -3.16. The company has a 50 day moving average of $41.98 and a 200-day moving average of $52.52.

Institutional Investors Weigh In On Soleno Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Raymond James Financial Inc. bought a new position in Soleno Therapeutics during the second quarter valued at approximately $25,000. Danske Bank A S bought a new stake in shares of Soleno Therapeutics during the 3rd quarter worth about $27,000. Global Retirement Partners LLC raised its stake in shares of Soleno Therapeutics by 519.0% in the 4th quarter. Global Retirement Partners LLC now owns 619 shares of the company’s stock valued at $29,000 after acquiring an additional 519 shares in the last quarter. Aster Capital Management DIFC Ltd acquired a new stake in Soleno Therapeutics in the 3rd quarter worth approximately $37,000. Finally, Caitong International Asset Management Co. Ltd bought a new stake in Soleno Therapeutics during the fourth quarter worth approximately $38,000. 97.42% of the stock is owned by hedge funds and other institutional investors.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.